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Long non-coding RNAs (lncRNAs) represent the
largest and most diverse class of non-coding
RNAs, comprising almost 16,000 currently annotated
transcripts in human and 10,000 in mouse. Here, we
investigated the role of lncRNAs in mammary tumors
by performing RNA-seq on tumor sections and orga-
noids derived from MMTV-PyMT and MMTV-Neu-
NDL mice. We identified several hundred lncRNAs
that were overexpressed compared to normal mam-
mary epithelium. Among these potentially oncogenic
lncRNAs we prioritized a subset as Mammary Tumor
Associated RNAs (MaTARs) and determined their
human counterparts, hMaTARs. To functionally vali-
date the role of MaTARs, we performed antisense
knockdown and observed reduced cell proliferation,
invasion, and/or organoid branching in a cancer-spe-
cific context. Assessing the expression of hMaTARs
in human breast tumors revealed that 19 hMaTARs
are significantly upregulated and many of these
correlate with breast cancer subtype and/or hor-
mone receptor status, indicating potential clinical
relevance.
INTRODUCTION
A number of studies over the past decade revealed that only 2%
of the human genome encodes for proteins, while as much as
80% can be transcribed in a cell-type-specific manner (Bertone
et al., 2004; Carninci et al., 2005; Djebali et al., 2012; ENCODE
Project Consortium, 2012; Kapranov et al., 2007; Katayama
et al., 2005; Okazaki et al., 2002). Non-coding transcripts are
subdivided into several classes, with long non-coding RNAs
(lncRNAs) representing the largest and most diverse class.
LncRNAs are defined by length, ranging from 200 nt to 138 kb.
Like mRNAs, they are transcribed by RNA polymerase II and
can be capped, spliced, and poly-adenylated. However,
lncRNAs lack a significant open reading frame, can be tran-
scribed from the sense or antisense orientation and commonlyCell Re
This is an open access article under the CC BY-Noriginate from introns or intergenic regions (Derrien et al., 2012;
Iyer et al., 2015; St Laurent et al., 2012). Members of this class
of non-coding transcripts have been implicated as regulatory
molecules in a variety of cellular functions (for review, see Berg-
mann and Spector, 2014; Kornienko et al., 2013; Rinn and
Chang, 2012).
In recent years, lncRNAs emerged as a novel class of regula-
tory molecules in cancer (for review, see Cheetham et al., 2013;
Prensner and Chinnaiyan, 2011; Shore et al., 2012; Wahlestedt,
2013; Wapinski and Chang, 2011). One of the first examples of a
lncRNA that has been studied in the context of breast cancer is
the HOX antisense intergenic RNA (HOTAIR) (Rinn et al., 2007). It
promotes mammary tumor invasion as well as metastasis and
acts as an independent predictor of patient survival rates (Gupta
et al., 2010; Rinn et al., 2007). Elevated expression levels of
another lncRNA BCAR4 were described to correlate with a
higher rate of metastasis and shorter patient survival (Xing
et al., 2014). Recently, lncRNA152 and lncRNA67 were shown
to play a role in the growth of breast cancer cell lines (Sun
et al., 2015). Eleanors, a new class of lncRNAs, were found to
be associated with breast cancer adaptation (Tomita et al.,
2015). In addition, genetic knockout or ASO-mediated knock-
down ofMalat1 results in the differentiation of mammary tumors
and significant reduction of metastasis in vivo (Arun et al., 2016).
Differential expression of a few additional lncRNAs has been
studied in the context of breast cancer, but as for most lncRNAs
the functional mechanisms remain elusive (for review, see Hansji
et al., 2014; Vikram et al., 2014). As only a handful of the almost
16,000 annotated lncRNAs (GENCODE v.24) have been func-
tionally characterized and studied in the context of breast
cancer, it is essential to perform an unbiased RNA sequencing
(RNA-seq) screen to identify the complement of lncRNAs that
exhibit altered expression in mammary tumors.
Here, we generated a comprehensive compendium of
lncRNAs that are differentially expressed in primary mammary
tumors compared to the normal mammary gland epithelium.
We performed RNA-seq analysis on three physiologically rele-
vant transgenic mouse models representing the luminal B
(MMTV-PyMT) and the HER2/neu-amplified (MMTV-Neu-NDL
and MMTV-Cre;Flox-Neo-Neu-NT) subtypes of breast cancer
(Andrechek et al., 2000; Guy et al., 1992; Siegel et al., 1999).
Among the 290 lncRNAs that are upregulated at least 2-fold inports 17, 261–274, September 27, 2016 ª 2016 The Author(s). 261
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Figure 1. The Transcriptome of MMTV-PyMT and MMTV-Neu-NDL Tumors
(A) Venn diagram indicating the overlap of differentially expressed genes across all datasets.
(B) Illustration of the number of genes significantly altered comparing tumor, day 0 and day 6 organoid datasets. Percentage of the transcriptome is denoted in
brackets; i.e., 142 genes represent 1.0% of the transcriptome in day 6 organoids compared to tumor sections.
(C) Transcript biotypes of the 142 differentially expressed genes comparing day 6 organoids to tumors. The majority (85%) of altered transcripts are protein-
coding. TEC, to be experimentally confirmed (GENCODE classification).
(D) Organoids were prepared from MMTV-PyMT, MMTV-Neu-NDL, and WT normal mammary epithelia and cultured for 6 days in Matrigel (left). UCSC genome
browser image (right) displays RNA-seq reads exemplarily at the Erbb2/neu locus. Vertical viewing range: 0–50.
(E) Principal component analysis comparing the transcriptome of organoids derived from WT (purple), MMTV-PyMT tumors (orange), and MMTV-Neu-NDL
tumors (green). Three clusters were detected according to the three different mouse models.
(legend continued on next page)
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the tumors compared to normal mammary epithelial cells we
prioritized 30 previously uncharacterized lncRNAs as mam-
mary-tumor-associated RNAs (MaTARs). In order to functionally
validate the MaTARs, we performed antisense knockdown
studies in primary cancer cells and 3D ex vivo mammary tumor
organoids. Our results indicate that independent knockdown of
20 of the 30 investigated MaTARs significantly reduce mammary
tumor cell proliferation, invasion, and/or collective cell migration.
Notably, we observed phenotypic changes upon MaTAR knock-
down in organoids derived from tumors but not in organoids
derived from normal mammary epithelial cells, indicating the
cancer-specific function of MaTARs. Furthermore, we confirmed
the overexpression of 19 humanMaTARs (hMaTARs) comparing
breast tumors to matched normal controls. Of those, 11 are ex-
pressed in a subtype-specific manner. We propose that these
previously uncharacterized lncRNAs might act as prognostic in-
dicators and/or drivers of breast tumor progression.
RESULTS
The Transcriptome of Luminal B and HER2-Amplified
Mammary Tumors
Recently, the culturing of mammary organoids in 3D artificial
extracellular matrix (ECM) hydrogels has gained popularity
over 2D cell culture approaches, especially for studying
mammalian development and disease (for review, see Clevers,
2016; Shamir and Ewald, 2014). Previous studies demonstrated
thatmammary branchingmorphogenesis can be recapitulated in
an organoid system by retaining its epithelial spatial organization
(Barcellos-Hoff et al., 1989; Ewald et al., 2008; Fata et al., 2007;
Nguyen-Ngoc et al., 2012). Furthermore, organoids developed
from tumors have the potential to serve as a rapid in vitro
screening system in drug development and ‘‘personalized
medicine.’’
We set out to validate that organoids indeed closely resemble
the gene expression signature of the tumors they were derived
from. Therefore, we removed mammary tumors from three
MMTV-PyMT mice and used one-half of each tumor for direct
RNA isolation from the tissue sections. The other half was
used to generate organoids, and RNA was extracted either
immediately following organoid preparation (day 0) or after
6 days of culturing in 3D Matrigel domes in the presence of
FGF2 (day 6). Comparative RNA-seq analyses revealed that
the global gene expression signature of mammary tumor orga-
noids is comparable to the tumor transcriptome (Figures S1A,
S1B, and S2A). Importantly, only 1% of the transcriptome (142
out of the 13,854 expressed genes) showed statistically signifi-
cant alterations (Figures 1A, 1B, and S1C) between the tumor
and the day 6 organoids. The affected genes were almost exclu-
sively (85%) protein coding genes (Figures 1C and S1D). Several
pathways involved in signaling and metabolism appeared
altered when taking into account genome-wide fluctuations
(Figure S2B).(F) Examples of GSEA datasets found upregulated in MMTV-Neu-NDL tumors (u
(G) Examples of GSEA datasets found downregulated in MMTV-Neu-NDL tumo
panel). FDR < 0.01.
See also Figures S1 and S2 and Tables S1 and S2.As our initial comparison demonstrated that organoids are a
valid model system to study lncRNA expression, we generated
organoids from MMTV-PyMT and MMTV-Neu-NDL mice. After
6 days in Matrigel, the transcriptome of the organoids was
analyzed using RNA-seq. To classify cancer-specific changes
in the gene expression signature in comparison to normal tissue,
we also generated and sequenced organoids from nulliparous
mammary glands of three wild-type friend virus B (FVB) females
(Figure 1D). The RNA-seq screen revealed significant changes in
both the coding and the long non-coding transcriptome, with a
total of 4,633 genes differentially expressed in MMTV-PyMT-
and 4,322 in MMTV-Neu-NDL-derived organoids. As an internal
control, we monitored the expression of Erbb2/neu, which was
overexpressed only in the MMTV-Neu-NDL organoids but not
in the PyMT or wild-type (WT) organoids (Figures 1D and S1F).
Principal component analysis and Euclidean distance plots
comparing WT mammary glands to the luminal B and HER2/
neu-dependent mammary tumors revealed distinct clustering
according to the tumor-driving transgene (Figures 1E and S1E).
Furthermore, we observed general and subtype-specific expres-
sion changes in cellular pathways (Figure S2C). Importantly,
gene-set enrichment analyses (GSEA) revealed that our mouse
mammary tumor organoid data resembled the transcriptome of
human breast cancer. For instance, the downregulated genes
of both models correlated well with expression signatures of
invasive breast cancer and metastatic tumors. A similar correla-
tion was found for upregulated genes in both datasets (Figures
1F and 1G).
Taken together, these data demonstrate that mouse mam-
mary carcinoma-derived organoids recapitulate the transcrip-
tome of luminal B and HER2/neu-amplified breast cancer and
are a reliable model system to study the expression of non-
coding RNAs.
Identification of Upregulated lncRNAs in Mammary
Organoids
We set out to generate a compendium of all currently annotated
lncRNAs that exhibit altered expression levels in mammary
tumors to provide a useful database for future research. We
identified 484 lncRNAs in MMTV-PyMT and 402 lncRNAs in
MMTV-Neu-NDL with an overlap of 122 between both models
that are differentially expressed in organoids derived from mam-
mary tumors compared to WT mammary epithelial cells (Fig-
ure 2A). These genes represent a diverse group in terms of their
biotypes and genomic location (Figures S3A and S3B). Biotypes
include ‘‘lincRNA’’ (long intergenic non-coding RNAs), ‘‘pro-
cessed pseudogenes,’’ ‘‘antisense’’ transcripts, and ‘‘processed
transcripts’’ (Figure S3A).
Furthermore, we aimed to focus on potentially oncogenic
lncRNAs that might act as drivers of tumor progression and
filtered our dataset for lncRNAs that are upregulated at least
2-fold. We identified 109 upregulated lncRNAs in MMTV-PyMT
(Table S1) and 207 in MMTV-Neu-NDL organoids (Table S2),pper panel) and MMTV-PyMT tumors (lower panel). FDR < 0.01.
rs (upper panel) and both MMTV-Neu-NDL and MMTV-PyMT tumors (lower
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Figure 2. Identification and Characterization
of MaTARs
(A) Computational analysis pipeline to identify
potentially oncogenic lncRNAs. Numbers indicate
genes significantly differentially expressed (FDR
adjusted p value < 0.1). Ensembl IDs and log2(fold
change) of all upregulated (> 2-fold) genes is pro-
vided in Tables S1 and S2.
(B) Coding probability of all 30 MaTARs according to
CPAT. Coding probability is plotted on a scale from
0 to 1, with 0 indicating ‘‘no coding potential’’ and
‘‘1’’ representing ‘‘high coding potential.’’ Inset: 63%
of all MaTARs are non-coding (no), whereas 37% are
potentially protein-coding (yes).
(C) Correlation of the CPAT coding label and lncRNA
biotypes. The 37%of transcripts with protein-coding
potential in B) are attributed to the pseudogene
fraction of MaTARs.
(D) Venn diagram illustrating overexpression of the 30
MaTARs in four tumor models. PyMT tumor, tumor
sections from MMTV-PyMT sections; Neu tumor,
tumor sections from MMTV-Cre;Flox-Neo-Neu-NT.
Most MaTARs are upregulated in several datasets.
(E) Length distribution of all 30MaTARs. Themajority
(20 MaTARs) is < 1,500 nt long.
(F) Number of exons per MaTAR. More than 50% of
MaTARs consist of one or two exons; only three
transcripts comprise more than four exons.
(G) MaTAR expression (variance-stabilizing trans-
formation [vst] counts) across ENCODE tissues,
wild-type (WT) organoids, and tumor organoids
and sections. The highest expression level for
18 MaTARs was detected in tumors. All MaTARs
are expressed in a tissue-specific manner. PyMT.
tumor, tumor sections from MMTV-PyMT sections;
Neu.tumor, tumor sections from MMTV-Cre;Flox-
Neo-Neu-NT. Counts are scaled per row.
(H) Connectivity between genes in the ‘‘mammary
epithelium’’ module is plotted against the module’s
eigengene correlation. Red dotted lines correspond
to first and third quartiles. Six MaTARs are in the
fourth quartile, denoted by high eigengene correla-
tion and intra-module connectivity.
SeealsoFiguresS1,S3, andS4andTablesS3andS4.with an overlap of 26 lncRNAs (Figure 2A, highlighted in gray in
Tables S1 and S2). Interestingly, very few of the identified tran-
scripts have been studied previously. One of these lncRNAs is
Trp53cor1 (also known as lincRNA-p21), which is upregulated
at least 4-fold in both mammary tumor models (Tables S1 and
S2) and has been implicated in p53/p21-dependent gene regula-
tion (Dimitrova et al., 2014; Huarte et al., 2010) as well as cancer
(Chou et al., 2015; Yang et al., 2014). Furthermore, the two plu-
ripotency-associated transcripts Platr4 and Platr7 were upregu-
lated more than 4-fold in MMTV-Neu-NDL organoids (Table S2).
Notably, Platr lncRNAs were identified in an RNA-seq screen of
embryonic stem cells (ESCs) and shown to be correlated to the
maintenance of the ESC expression profile (Bergmann et al.,
2015). We performed coding potential analysis on all 290 upre-
gulated lncRNA genes (443 associated transcripts in total) using
the Coding-Potential Assessment Tool (CPAT) (Wang et al.,
2013). Our results revealed that 75% of the 443 identified tran-
scripts do not exhibit coding potential (Figures S3C–S3F) despite264 Cell Reports 17, 261–274, September 27, 2016including pseudogenes in our analysis. As expected, we observe
a good correlation between coding probability and open reading
frame (ORF) length but not RNA length (Figures S3E and S3F).
We further characterized the identified differentially expressed
lncRNA genes regarding shared transcription factor binding sites
at their promoter regions. To do so, we performedmotif analyses
in the regions of 900 to +100 bp around the transcription
start site (TSS) of all differentially regulated lncRNA genes, iden-
tified in both PyMT and Her2/neu organoids. For downregulated
promoters, we observe the enrichment of a rather rare motif
matching Zbtb33/Kaiso as well as motifs for NF-kB and CEBP
(Figure S4A). In contrast, upregulated lncRNA genes seem to
be primarily regulated by androgen receptor (AR) and p63
(Figure S4B).
To narrow down the long list of candidates to the ones with
highest potential to impact mammary tumors, we prioritized
the transcripts further based on several stringent criteria: (1) sta-
tistical significance (false discovery rate [FDR] adjusted p value
<0.1), (2) at least 2-fold upregulation in tumor organoids and/or
tumor sections compared to normal mammary organoids, (3)
sufficient read coverage per transcript to eliminate very lowly
abundant RNAs (Figure S1G), (4) human conservation based
on sequence and/or synteny, (5) location in an intergenic
genomic region, and (6) lack of highly repetitive elements. The
last two points ensure knockdown specificity, i.e., that antisense
oligonucleotides (ASOs) can be designed for the lncRNA of inter-
est while avoiding potential off-target effects. Out of 290 upregu-
lated lncRNAs, 30 transcripts fulfilled the above-mentioned
criteria and were selected as an initial subset for further charac-
terization. All 30 are overexpressed in at least four out of the five
sequenced PyMT organoid datasets as well as significantly up-
regulated in PyMT tumor sections (Figure 2D). We also included
RNA-seq data from MMTV-Cre;Flox-Neo-Neu-NT tumors, a
second model for the HER2/neu-amplified subtype of human
breast cancer, to further refine our candidate lncRNAs. We
termed the prioritized transcripts Mammary Tumor Associated
RNA 1-30 (MaTAR1-30). A complete list of their official gene
IDs and expression levels in all evaluated mammary tumor
models is presented in Table S3. Of the 30 MaTARs, only
MaTAR4 and MaTAR8 have been characterized in the past.
MaTAR4 (Hoxa transcript antisense RNA, myeloid-specific 1;
Hotairm1) has been implicated in myelopoiesis and myeloid
maturation (Zhang et al., 2009; 2014). MaTAR8 (lncRNA-
Smad7) has been described as a TGF-b-regulated antisense
transcript of Smad7 inhibiting apoptosis in mouse breast cancer
cells (Arase et al., 2014). We tested the coding potential of all
MaTARs using CPAT (Wang et al., 2013). While 60% of the
MaTARs were classified as non-coding, 40% were predicted
to be coding, attributed to the pseudogene fraction (Figures 2B
and 2C). We further characterized theMaTARs according to their
total length and number of exons (Figures 2E and 2F). MaTARs
range in size from 291 to 4867 nt with themajority of MaTARs be-
ing shorter than 1,500 nt. More than half of all MaTARs consist of
one or two exons, only 10% show complex structures with more
than four exons.
In order to compare the expression levels of MaTARs in mam-
mary tumors to other tissue types, we analyzed the ENCODE
expression datasets of adult mouse tissue as well as embryonic
stemcells (Bergmannet al., 2015) (Figure 2G).Our results confirm
the general notion of tissue-specific expression of lncRNAs
(Cabili et al., 2011; Derrien et al., 2012), with the majority of the
MaTARs (18 out of 30) being expressed at very low levels in tis-
sues other than mammary tumors. The remaining 12 MaTARs
(MaTAR1, 3, 7, 9, 10, 11, 12, 18, 19, 23, 26, and 27) are also over-
expressed in mammary tumors compared to normal mammary
glands, but in addition these MaTARs are present in comparable
levels in at least one other tissue type.
To further characterize MaTARs in the context of global gene
expression and to assess their potential role in mammary tumor
progression, we performed weighted gene correlation network
analysis (WGCNA) (Langfelder and Horvath, 2008). We identified
39 modules with a median gene number of 274. Remarkably, 17
of the 30 MaTARs are residing within the same module. This
particular module (‘‘blue,’’ Table S4) is enriched for genes that
are highly expressed in our RNA-seq datasets, both in the normal
mammary gland organoids as well as mammary tumors andhence was termed the ‘‘mammary epithelium’’ module. It is
rather large, comprising 5,744 genes in total. Interestingly, only
2,588 of the module genes are classified as ‘‘protein coding,’’
emphasizing the tissue specificity of non-coding RNA species
as well as their potential functional role.
In order to identify key drivers of the module, we focused on
potential ‘‘hub genes’’ with high intra-module connectivity
(>1,550) and very good correlation with the module eigengene
(R0.9), marked in red in Figure 2H. At least six MaTARs
(MaTAR5, 6, 9, 15, 16, and 30) fall into this region, indicating their
importance within the module. Notably, 12 of the 17 MaTARs in
the ‘‘mammary epithelium’’ module were also expressed higher
in tumor tissue compared to normal organs (Figure 2G). This in-
dicates that MaTARs are excellent marker genes and sufficient
to stratify mammary epithelia from other tissue types. GO anal-
ysis of the module revealed association with several interesting
biological processes that are in agreement with the top ‘‘hub
genes,’’ including 33 ribosomal and small nucleolar RNA
(snoRNA) genes, several components of the spliceosome, cyclo-
oxygenase 2 and 3, but also typical marker genes for mammary
epithelia like caseins and lactalbumin.
In summary, our findings demonstrate that we identified a
module related to mammary epithelial development and/or
mammary carcinogenesis and suggest that MaTARs are likely
to play key roles in these functional processes.
Knockdown of MaTARs Decreases Cell Viability and
Invasion
The results of our computational approach suggested that mul-
tiple MaTARs may contribute to mammary cancer progression.
We tested this possibility by performing knockdown experiments
of all 30 MaTARs using antisense oligonucleotides (ASOs)
initially in primary MMTV-PyMT tumor cells. These oligonucleo-
tides are short (20-mer), single-stranded DNA molecules con-
taining phosphorothioate-modified nucleotides as well as modi-
fications of the 20-ribose (5-10-5 20-MOE gapmer) (for review, see
Geary et al., 2015). Importantly, we found that the uptake of
ASOs in primary mammary tumor cells is efficient without the
use of transfection agents, a mechanism that has been studied
in detail in hepatocytes (Koller et al., 2011). One of the candi-
dates, MaTAR2, was not expressed at levels consistent enough
for reliable quantification using qRT-PCR and hence was
excluded from knockdown experiments. For each of the remain-
ing 29 MaTARs, we tested ten different specific ASOs and
achieved knockdown efficiencies ranging from 38% to 89%after
24 hr using 5 mM of the most potent ASO (Figure S5A).
To initially investigate the functional impact of MaTAR downre-
gulation on tumor cells, we combined the ASO treatment with
cell viability or invasion assays (Figures 3A and 3B). Significant
changes were defined as a consistent reduction R25% of
viability or invasion compared to untreated control cells. Interest-
ingly, MTT assays revealed that the knockdown of MaTAR12
leads to a 50% decrease in cell viability (Figure 3A), an effect
comparable to ASO-mediated knockdown of Eg5 that served
as a positive control (Koller et al., 2006). Knockdown of three
additional candidates (MaTAR11, 18, and 20) resulted in
R25% decrease of cell viability. We did not observe an effect
on cell viability with a scrambled ASO control (scASO)Cell Reports 17, 261–274, September 27, 2016 265
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(Figure 3A). To confirm that our results obtained with theMTT as-
says are in fact detecting differences in cell viability, we per-
formed assays measuring protease activity within living cells
on a subset of the MaTARs and obtained similar results
(Figure S5B).
In addition, we performed invasion assays of tumor cells in 96-
well Boyden chamber plates upon ASO-mediated knockdown.
We used serum-free medium as a positive control and detected
a 25%–45% reduction of tumor cell invasion upon independent
knockdown of 15 candidates (MaTAR8, 9, 13, 14, 15, 16, 17, 19,
20, 21, 23, 24, 25, 28, and 29; Figure 3B). While knockdown of
several MaTARs impacts either the viability or the invasive
potential of mammary tumor cells, indicating specific roles of
the different non-coding transcripts in cellular processes, only
MaTAR20 showed effects in both assays (Figure 3C). Of the 29
tested MaTARs, 11 lncRNAs (MaTAR1, 3, 4, 5, 6, 7, 10, 22, 26,
27, and 30) did not exhibit significant effects on cell growth or in-
vasion upon knockdown.
As an example validation of the antisense knockdown experi-
ments, we used the CRISPR/Cas9 system (Ran et al., 2013) to
generate a knockout clone of MaTAR25, the lncRNA that ex-
hibited the most dramatic impact on cell invasion (45%, Fig-
ure 3B). Indeed, the genetic loss of MaTAR25 significantly
reduced tumor cell invasion as well (55%, Figures S5C–S5E),
recapitulating the ASO-mediated knockdown. Our results indi-
cate that our initial computational selection of upregulated
lncRNAs identified a number of transcripts that have the poten-
tial to impact tumor cell growth or invasion.
KnockdownofMaTARs InhibitsCollectiveCellMigration
in Organoids
To further elucidate the functional role of MaTARs in a more
physiological context, we performed ASO-mediated knockdown
experiments in mammary tumor organoids (Barcellos-Hoff et al.,
1989; Ewald et al., 2008; Fata et al., 2007; Nguyen-Ngoc et al.,
2012). As for primary tumor cells, we found that mammary orga-
noids perform transfection-free uptake of ASOs.
For the 29 tested MaTARs, we observed knockdown effi-
ciencies in organoids ranging from 30%–68% after 6 days of
treatment using 4 mM of the most potent ASO (Figure S6A). Un-
treated aswell as scASO-treatedMMTV-PyMT organoids gener-
ally exhibit branching in about 70%–75% of all organoids. Upon
ASO-mediated knockdown, we detected a significant decrease
(25%–50% less compared to untreated organoids) in branching
morphogenesis for 11 candidates (MaTAR6, 11, 12, 16, 17, 18,
19, 20, 25, 26, and 28; Figure S6B). Interestingly, many of the
MaTARs whose knockdown interfered with cell viability and/or
invasion in 2D assays also exhibited a branching defect in orga-Figure 3. ASO-Mediated Knockdown of MaTARs in Primary Tumor Ce
Primary mammary tumor cells were treated with 5 mM of the most potent ASO fo
(A) MTT assay after ASO-mediated knockdown of MaTARs. Cell viability is norma
negative control; ASO knockdown of Eg5 was used as a positive control. Bars d
(B) Invasion assay after ASO-mediated knockdown of MaTARs. Like A, serum-fr
(C) Summary of observed effects on cell viability, cell invasion, and organoid br
untreated cells (= 100%). Reduction of viability, invasive potential, or branching o
The color legend is indicated.
See also Figure S5.noids (Figure 3C). However, this correlation is not true for all
MaTARs, indicating that 2D culture models different aspects of
tumor cell growth than organoids.
As expected, we do not see phenotypic changes upon
ASO-mediated downregulation for all MaTARs. While we
obtained a knockdown efficiency of 55% for MaTAR8
(ENSMUSG00000092569, Gm20544, lncRNA-Smad7), we did
not observe a loss of branching or any other phenotypic change
in organoids (Figure 4D, additional images in Figure S6D). This is
in agreement with previous findings describing that MaTAR8 is
not involved in epithelial mesenchymal transition (EMT) (Arase
et al., 2014). Our results indicate that different MaTARs might
impact different aspects of tumor biology.
We further focused on MaTAR16 (ENSMUSG00000086249,
Gm12724), MaTAR18 (ENSMUSG00000085873, Ttc39aos1),
and MaTAR26 (ENSMUSG00000097378, B230208H11Rik), as
these three transcripts showed very distinct organoid pheno-
types upon ASO-mediated knockdown (Figure 4A). The three
RNAs represent different transcript biotypes with MaTAR16
being classified as ‘‘processed transcript,’’ MaTAR18 as ‘‘anti-
sense,’’ and MaTAR26 as ‘‘lincRNA.’’ Both MaTAR16 and
MaTAR26 are part of the ‘‘mammary epithelium’’ module, while
MaTAR18 resides in another highly interesting module that is
comprised of the gene-expression signature for embryonic
stem cells and embryonic liver. This module is associated with
GO terms related to replication and the cell cycle.
Knockdown experiments were performed with two different
ASOs for each transcript to ensure that the observed pheno-
types are not caused by off-target effects. Phenotypes for both
ASOs are shown in comparison to organoids that were either un-
treated or treated with scASO (Figure 4A with additional images
in Figure S6C). While knockdown of MaTAR16 and MaTAR26
completely abolished organoid branching, downregulation of
MaTAR18 resulted in organoids without defined branches but
with a ‘‘rough’’ surface. In addition, we observed that organoids
treated with ASOs targeting MaTAR16 tend to be smaller
compared to untreated or scASO-treated organoids (Figure 4A).
Individual knockdown efficiencies are displayed in Figure 4B and
correlate well with the loss of branching (Figure 4C). Compared
to untreated controls, we detected a reduction in branching of
38% for MaTAR16, 40% for MaTAR18, and 35% for MaTAR26
with the best ASO, respectively.
To further elucidate the role of MaTAR16, MaTAR18, and
MaTAR26, we performed ASO-mediated knockdown in control
organoids derived from WT nulliparous mammary glands.
Knockdown efficiencies of the ASOs are comparable to the ex-
periments in tumor organoids (Figure S7A). Importantly, we do
not see a pronounced loss of branching in the normal mammarylls
r 24 hr.
lized to untreated cells (‘‘Control’’). A scrambled ASO (‘‘scASO’’) was used as a
enote the mean of two replicates ± SE.
ee medium was used as positive control.
anching upon ASO-mediated knockdown of MaTARs. Data are normalized to
fR 25% compared to untreated cells was defined as a significant difference.
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gland organoids, strongly indicating the cancer-specific role of
these three lncRNAs (Figure 4E). In addition, this experiment
serves as another control, confirming that the observed reduc-
tion in branching morphogenesis of tumor organoids is not due
to ASO induced toxicity or off-target effects.
To exclude the possibility that our results are dependent on the
genomic background of the mice, we confirmed the findings for
MaTAR16, MaTAR18, and MaTAR26 in organoids derived from
C57Bl/6 MMTV-PyMT tumors (Figure 4F). Knockdown effi-
ciencies and branching quantifications are shown in Figure S7B.
Human MaTARs Are Overexpressed in Breast Cancer
To confirm the relevance of MaTARs in breast cancer, we set out
to identify human orthologs of all MaTAR genes. We compared
mouse and human transcripts on the level of both sequence
conservation and genomic location. If the mouse MaTAR
sequence matched an annotated human gene using the BLAT
alignment tool, then the respective transcript was defined as
the human counterpart. For instance, BLAT results for MaTAR1
indicate sequence identity in the human genome as well as a
similar genomic context. It matches the last exon of a longer
lncRNA (LINC00461, ENSG00000245526) in close spatial prox-
imity of a miRNA gene (Figure 5A). The sequence of MaTAR1
spans 2,419 bp in the human genome with a sequence identity
of 92.6% and a BLAT score of 1438. This genomic region is high-
ly conserved in vertebrates as indicated by the PhyloP conserva-
tion track (Figure 5A). The sequence-based approach is not
informative for pseudogenes, as the parental protein-coding
genes are the best sequence matches, e.g., FAM96B for a
Fam96b pseudogene such as hMaTAR2 (Table S5). As many
non-coding RNAs are conserved between different species on
the level of genomic location rather than based on sequence,
possibly implying functional conservation (Diederichs, 2014;
Ulitsky et al., 2011), we extended our analysis to synteny by
analyzing the nearest neighboring genes of each MaTAR
gene. The complete list of the genomic locations of potential
hMaTARs is provided in Table S5. Interestingly, many hMaTARs
are located in clusters of two or more non-coding genes in the
genome, resulting in a total of 41 identified potential hMaTARs.
Experimental validation will be necessary to identify the correct
human counterpart unambiguously.Figure 4. ASO-Mediated Knockdown of MaTARs in Mammary Organo
Organoids were treated with 4 mM of specific ASOs for 6 days. Statistical signifi
**p < 0.01, ***p < 0.01. Scale bar, 100 mm
(A) Differential interference contrast (DIC) images of tumor organoids upon k
or MaTAR26 are shown. Knockdown of MaTAR16 and MaTAR26 leads to a lo
protrusions.
(B) qRT-PCR to determine the knockdown efficiency of two specific ASOs per Ma
replicates ± SD.
(C) Quantification of tumor organoid branching upon knockdown with two specifi
ASO-mediated knockdown efficiency. Black and gray bars indicate the percen
branched organoids. The mean of three biological replicates is shown; total num
(D) Knockdown ofMaTAR8 using two specific ASOs in tumor organoids. Upper pa
three replicates ± SD. Middle panel: quantification of organoid branching. The m
per treatment = 300. Lower panel: DIC images of organoids upon knockdown.
(E) DIC images of WT normal mammary epithelia organoids upon knockdown wi
shown.
(F) DIC images of C57Bl/6 MMTV-PyMT organoids upon knockdown with the tw
See also Figures S6 and S7.To evaluate the expression status of the potential hMaTARs, we
analyzed RNA-seq data of The Cancer Genome Atlas (TCGA) by
comparing breast tumors to matched normal tissues of 103 pa-
tients. Out of the 41 hMaTARs, we were able to obtain differential
gene expression for 40 (Table S6). hMaTAR3 dropped out due to
insufficient read coverage. Notably, 28 hMaTARs were found to
be upregulated in breast tumors, 19 of those with high statistical
significance (adjusted p < 0.05), confirming that our initial RNA-
seq screen in mouse models identified multiple lncRNAs that
are potentially clinically relevant. We further investigated whether
hMaTARs are expressed in a subtype-specific manner by
analyzing all TCGA breast tumor samples with subtype informa-
tion (463 datasets). Of the 19 upregulated hMaTARs, 11 were ex-
pressed significantly different (q < 5.00E-11, same range as
PAM50genes [Parker et al., 2009]) among the five TCGAsubtypes
‘‘basal,’’ ‘‘Her2-amplified,’’ ‘‘luminal A,’’ ‘‘luminal B,’’ and ‘‘normal-
like’’ (Table S7; Figure S8). In addition, hMaTAR4 and hMaTAR23
showed strong subtype specificity, indicating that these lncRNAs
may be clinically relevant in certain subtypes despite not being
significantly upregulated across the board (Table S6).
Here, we focus on hMaTAR1, as this lncRNA was upregulated
the most in our original screen (80- and >100-fold in Her2-ampli-
fied and PyMT tumors, respectively). We found hMaTAR1 to be
significantly overexpressed in breast tumors compared to normal
breast tissue (Table S6). We confirmed our analysis using previ-
ously published TCGA datasets (Yan et al., 2015) and detected
a slight, but significant, upregulation in kidney carcinoma as
well as substantial overexpression in lung squamous cell carci-
noma (Figure 5B). Moreover, we observed statistically significant
differences in the expression levels of hMaTAR1 comparing
different subtypes of breast cancer, with lowest levels in the
luminal A and highest levels in the basal subtype (Figure 5C; Table
S7). Notably, we also detected a strong correlation of high
hMaTAR1 levels and negative ER/PR status (Figure 5D; Table
S7), matching the subtype data. Similar observations were
made for seven additional hMaTARs (Table S7; Figure S9). Inter-
estingly, the high expression levels in ER-/PR- tumors did not
correlate with a genomic amplification of the hMaTAR1 locus
(data not shown), indicating that upregulation of this lncRNA
may be caused by changes in gene expression and/or epigenetic
factors. Survival analysis revealed that patients with low levels ofids
cance was determined using a two-tailed, paired Student’s t test; *p < 0.05,
nockdown with the two most potent ASOs targeting MaTAR16, MaTAR18,
ss of branching while knockdown of MaTAR18 results in organoids with tiny
TAR, normalized to untreated cells (‘‘Control’’). Bars denote the mean of three
c ASOs per MaTAR. Reduction of organoid branching correlates directly with
tage of branched organoids ± SD; white bars indicate the percentage of un-
ber of assayed organoids per treatment = 300.
nel: qRT-PCR to determine the knockdown efficiency. Bars denote the mean of
ean of three biological replicates is shown; total number of assayed organoids
th the two most potent ASOs targeting MaTAR16, MaTAR18, or MaTAR26 are
o most potent ASOs targeting MaTAR16, MaTAR18, or MaTAR26 are shown.
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Figure 5. hMaTARs Are Overexpressed in
Breast Cancer
(A) Identification of a human MaTAR gene based
on sequence identity. The upper panel re-
presents the mouse genome (mm10); the lower
panel represents the human genome (hg38).
MaTAR1 is highlighted (ENSMUST00000052354),
ENSMUST00000083490 = miR-9-2.
(B) Expression fold change of hMaTAR1 published
TCGA RNA-seq datasets compared to the
respective normal tissue. FDR < 0.00001. KIRC,
kidney renal clear cell carcinoma; BRCA, breast
invasive carcinoma; LUSC, lung squamous cell
carcinoma.
(C) Differential gene expression of hMaTAR1 in
subtypes of human breast cancer. Her2, HER2
amplified, LumA, luminal A; LumB, luminal B.
(D) Correlation of hMaTAR1 expression to estro-
gen receptor (ER, left) and progesterone receptor
(PR, right) status.
(E) Survival curve for the luminal B subtype,
comparing patients in the upper quartile of
hMaTAR1 expression to patients in the lower
quartile of hMaTAR1 expression.
(F) Reactome pathways positively or negatively
correlated to hMaTAR1 expression.
See also Figures S8 and S9 and Tables S5–S7.hMaTAR1 survive on average 1,500 days (approximately 4
years) longer than patients with high levels of this lncRNA (Fig-
ure 5E). In addition, we performed pathway analysis of TCGA
data and observed a significant positive correlation of pathways
such as ‘‘cell cycle’’ and ‘‘DNA replication,’’ hinting to a high pro-
liferative rate of tumors with elevated hMaTAR1 levels (Figure 5F).
In summary, we performed an RNA-seq screen to identify
lncRNAs that are upregulated inmammary tumors and represent
potentially oncogenic transcripts. We identified 109 lncRNAs
that are upregulated at least 2-fold in MMTV-PyMT and 207
that are upregulated at least 2-fold in MMTV-Neu-NDL tumors.270 Cell Reports 17, 261–274, September 27, 2016Among these transcripts we prioritized
30 as MaTARs and showed that ASO-
mediated knockdown of 20 MaTARs
significantly reduces cell proliferation
and/or invasion in 2D cell culture as well
as branching in organoids. Phenotypic
changes were only observed in organoids
derived from mammary tumors but not
normal mammary glands, indicating a
specific role of MaTARs in cancer. A sig-
nificant number of hMaTARs are overex-
pressed in human breast tumors and their
expression signature correlates with sub-
type and hormone receptor status.
DISCUSSION
In recent years, high-throughput seq-
uencing studies have begun to shed light
on the emerging role of non-coding tran-
scripts in cancer. Several studies suggestlncRNAs as novel prognostic biomarkers, tumor suppressors,
and oncogenes (for review, see Cheetham et al., 2013; Huarte,
2015; Prensner and Chinnaiyan, 2011; Shore et al., 2012; Wah-
lestedt, 2013; Wapinski and Chang, 2011). However, many
global gene expression studies were performed in human cancer
cell lines. There are several potential caveats to using cell lines to
study tumor biology, such as adaption to growth in vitro on plas-
tic dishes, lack of corresponding normal tissue controls, cell
immortalization, lack of a physiological ECM, and accumulation
of chromosomal aberrations due to continued passaging. Impor-
tantly, transcriptome analyses revealed that commonly used
cancer cell lines often do not represent tumors well enough and
that tumors cluster closer to their corresponding normal tissues
than to cell lines (Domcke et al., 2013; van Staveren et al., 2009).
Primary 3D ex vivo organoids resemble the organization and
physiology of native epithelia much better than cancer cell lines
grown in 2D, and additionally model interactions with the ECM
(Boj et al., 2015) (for review, see Clevers, 2016; Sachs and
Clevers, 2014; Shamir and Ewald, 2014). To investigate whether
organoidsmirror the tumor on the level of global gene expression
as well, we performed the first RNA-seq screen comparing the
transcriptome of organoids to the mammary tumors from which
they were derived. Importantly, our data demonstrate that non-
coding RNA levels seem to remain virtually unchanged. Our find-
ings support the potential use of patient-derived organoids as a
model system to study tumor biology and to model drug re-
sponses (‘‘personalized medicine’’ [Boj et al., 2015]; for review,
see Lancaster and Knoblich, 2014; Shamir and Ewald, 2014).
We performed an unbiased RNA-seq screen to categorize the
compendium of differentially regulated lncRNAs in mammary tu-
mors compared to normal mammary epithelial cells. While we
confirmed several known cancer-associated lncRNAs such as
lincRNA-p21 in our screen, the majority of the 764 differentially
expressed candidates have not been described previously in
the context of cancer. Our study emphasizes the importance
of unbiased screening approaches and represents a valuable
resource of lncRNAs to pursue in regard to their involvement in
mammary carcinogenesis and as prognostic and/or therapeutic
targets.
Genome-wide gene expression studies often lack systematic
functional validation. Here, we characterized the identified
mammary tumor associated lncRNAs using both computational
approaches and molecular assays. Motif analysis of all differen-
tially regulated lncRNAs in our study revealed specific regula-
tors for up- and downregulated non-coding RNA genes.
Repressed lncRNAs show an enrichment in their promoter re-
gions for the transcription factor Kaiso, which has been
described to act as an oncogene by DNA methylation-depen-
dent silencing of tumor suppressor genes in colon cancer
(Lopes et al., 2008). Furthermore, we detect an enrichment of
motifs for NF-kB and CEBP, two transcription factors that
have been implicated in aggressive breast cancer and EMT
(Bundy and Sealy, 2003; Huber et al., 2004). Upregulated
lncRNA promoters are enriched for AR and p63 binding motifs.
AR was described to stimulate breast tumor progression but its
effect depends on the ER status of the patient (for review, see
Chang et al., 2014). The transcription factor p63 is required to
initiate collective cell migration and invasion in tumor organoids
and in vivo (Cheung et al., 2013). Interestingly, our motif analysis
revealed that the same regulators that control known tumor
suppressor genes might downregulate the identified lncRNAs,
while upregulated lncRNAs might be activated by factors that
also control known oncogenes.
In addition to computational predictions, we performed ASO-
mediated knockdown assays. Of the 290 upregulated candi-
dates, we prioritized 30 lncRNAs, termed MaTARs, and
observed that independent downregulation of 20 MaTARs leads
to a significant reduction of cell proliferation, invasion, and/or
collective cell migration. Given that the results of individualknockdown experiments were characteristic for the respective
non-coding RNA, we propose that each MaTAR might impact
different aspects of tumor cell growth and/or metastasis. Inter-
estingly, knockdown of MaTAR16, MaTAR18, and MaTAR26 re-
sulted in reduced branching of tumor organoids, but not normal
mammary organoids. Our findings suggest that MaTARs might
be dispensable for normal mammary epithelial growth but
seem to be essential in the context of cancer.
Based on our extensive analysis in mouse, we propose that
the human orthologs of MaTARs are likely impacting human
breast cancer progression. In this regard, concerns are often
raised about the lack of conservation between mouse and hu-
man lncRNAs (Derrien et al., 2012). Unlike protein-coding genes,
the functions of lncRNAs are not necessarily directly linked to
their nucleotide sequence but are often dependent on RNA sec-
ondary structure folding or syntenic transcription (Diederichs,
2014). Synteny between non-coding and protein-coding genes
is frequently conserved across species (Ulitsky et al., 2011).
Importantly, we identified potential human counterparts for all
MaTAR genes and demonstrated that at least 50% of them are
overexpressed in breast tumors compared to matched normal
controls. The TCGA data analysis confirms that our RNA-seq
screen inmousemodels identified lncRNAs that act as important
regulators of mammary tumor progression and whose functions
may be conserved in the human system. Similar to the mouse
studies, we revealed that hMaTARs can be expressed in a breast
cancer subtype-specificmanner or generally upregulated across
all subtypes.
Of the 20 MaTARs that impact cell proliferation, invasion, and/
or organoid branching, 11 have human orthologs that are upre-
gulated in breast cancer. We suggest that these lncRNAs are
likely drivers of tumor progression and could potentially be of
clinical relevance. Future studies will reveal the detailed molecu-
lar mechanism by which hMaTARs act as well as their prognostic
and therapeutic potential.
EXPERIMENTAL PROCEDURES
Organoid Culture
Organoids from wild-type nulliparous mammary glands, MMTV-PyMT tumors,
and MMTV-Neu-NDL tumors were prepared and cultured as described previ-
ously (Ewald, 2013). For MMTV-PyMT mice, individual tumors were isolated
and organoids were generated in a tumor-specific manner. Mammary epithe-
lial fragments (organoids) were mixed with growth factor-reducedMatrigel at a
concentration of 5 organoids/mL and plated as 80-mL domes in 24-well dishes.
Organoids were grown in DMEM/F12 medium supplemented with 13 ITS (in-
sulin, transferrin, and sodium selenite) media supplement, 1% penicillin/strep-
tomycin, and murine FGF2 (2.5 nM). Animal experiments were carried out in
the Cold Spring Harbor Laboratory Animal Shared Resource in accordance
with Institutional Animal Care and Use Committee-approved procedures
(see the Supplemental Experimental Procedures).
RNA Sequencing
Total RNA was isolated either directly from cryosections of the tumor tissue or
from organotypic epithelial cultures using TRIzol according to the manufac-
turer’s instructions. For tissue sections, the tumors were embedded in optimal
cutting temperature (OCT) and cryosectioned. Sections from the middle of the
tumor were stained using toluidine blue and assayed regarding the homogene-
ity of the section. Homogenous 30-mm sections comprising >90% malignant
cells were immediately dispersed and homogenized in TRIzol. RNA quality
was assayed by running an RNA 6000 Nano chip on a 2100 Bioanalyzer. ForCell Reports 17, 261–274, September 27, 2016 271
high-throughput sequencing, RNA samples were required to have an RNA
integrity number (RIN) R9. TruSeq (Illumina) libraries for poly(A)+ RNA-seq
were prepared from 0.5–1 mg RNA per sample. To ensure efficient cluster
generation, an additional gel purification step of the libraries was applied.
The libraries were multiplexed (four to six libraries per lane) and sequenced
paired-end 101 bp on the HiSeq2000 platform (Illumina), resulting in an
average 40 Mio reads per library.
ASO-Mediated Knockdown in Primary Cells
MMTV-PyMT primary cells were seeded at a density of 20,000 cells/well
(100 mL per well) into 96-well plates. Transfection-free uptake of ASOs was
accomplished by adding 5 mM of either a MaTAR-specific ASO or scrambled
ASO (scASO) to the primary cell culture medium immediately after seeding
the cells. ASO sequences are provided in Table S8. Cells were incubated
for 24 hr at 37C and RNA was isolated using the RNeasy 96 kit (QIAGEN) ac-
cording to the manufacturer’s instructions. RNA samples were used directly
in a one-step 384-well qRT-PCR (QuantiTect SYBR Green RT-PCR Kit,
QIAGEN) on an Applied Biosystems 7900HT Fast Real-Time PCR System.
qRT-PCR conditions were as follows: 30 min at 50C for reverse transcrip-
tion, 15 min at 95C for the initial activation step followed by 40 cycles of
15 s at 94C, 30 s at 60C. Peptidylprolyl isomerase B (cyclophilin B) was
used as an endogenous control to normalize each sample, and relative
expression results were calculated using the 2DDCt method. A list of primers
used is provided in Table S9.
ASO-Mediated Knockdown in Organoids
Organoids were seeded at a density of 5 organoids/mL and plated as 80 mL
domes in 24-well dishes. Transfection-free uptake of ASOs was accom-
plished by adding 4 mM of either a MaTAR-specific ASO or scASO to the or-
ganoid culture medium 15–20 min after the organoids were plated in Matrigel
domes. Organoids were incubated for 6 days at 37C and both medium, and
ASOs were replenished at day 3. ASO sequences are provided in Table S8.
Total RNA was isolated using TRIzol. DNase I treatment was performed for
15 min at room temperature (RT) to remove contaminating DNA. cDNA syn-
thesis was carried out using TaqMan Reverse Transcription reagents (Life
Technologies) and random hexamers according to the manufacturer’s in-
structions. Real-time qPCR was performed using the Power SYBR Green
Master Mix (Life Technologies) in 384-well plates using the Applied Bio-
systems 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific).
Cycling conditions were as follows: 10 min at 95C followed by 40 cycles
of 15 s at 95C, 1 min at 60C. Primer specificity was initially tested by
agarose gel electrophoresis and subsequently monitored by melting curve
analysis. Peptidylprolyl isomerase B (cyclophilin B) was used as an endoge-
nous control to normalize each sample and relative expression results were
calculated using the 2DDCt method. A list of primers used is provided in Ta-
ble S9. For visualization purposes and quantification of organoid branching,
images were acquired using an Axio-Observer Live Cell inverted microscope
(Zeiss) at 103 magnification.
TCGA Data Analysis
Analysis of TCGA data (Cancer Genome Atlas Network, 2012) was performed
on the Cancer Genomics Cloud hosted by Seven Bridges Genomics (https://
www.sbgenomics.com). For differential gene expression comparing 103
breast tumor samples to matched normal controls, raw RNA-seq reads
were mapped to hg38 and counted as described above. The GENCODE
v.24 gene transfer format (GTF) was used as a reference. Fold changes
calculated for individual patients were averaged and statistical significance
was calculated using Wilcoxon rank tests; p values were adjusted using
the Benjamini and Hochberg method. Subtype-specific analysis, survival,
and pathway analysis are described in detail in the Supplemental Experi-
mental Procedures.
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